Intellia Therapeutics

Yahoo Finance • 2 months ago

Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds?

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds.In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against the other promising biotech stocks.... Full story

Yahoo Finance • 3 months ago

2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street

Should investors follow the advice of big names on Wall Street? One challenge in doing so is that sometimes analysts have very different takes. Fortunately, there's some agreement on other occasions. Consider these two companies: Block(NY... Full story

Yahoo Finance • 5 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

As you might know, Intellia Therapeutics, Inc. (NASDAQ:NTLA) last week released its latest second-quarter, and things did not turn out so great for shareholders. It was not a great statutory result, with revenues coming in 64% lower than t... Full story

Yahoo Finance • 5 months ago

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

Intellia Therapeutics, Inc. NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung disease associated with alpha-1 antitrypsin deficiency (AATD) NTLA-3001 is Intell... Full story

Yahoo Finance • 7 months ago

Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought

Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer of Ark Invest doesn't mind going against... Full story

Yahoo Finance • 7 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Cathie Wood doesn't take any trading days off. The co-founder and CEO of Ark Invest publishes her transactions for the family of exchange-traded funds she manages. She didn't make a lot of moves on Wednesday, but the ones she did make are... Full story

Yahoo Finance • 7 months ago

Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?

Via her ARK Innovation ETF(NYSEMKT: ARKK), portfolio manager Cathie Wood makes a lot of biotech bets, often on companies that are at the cutting edge of innovation in science and technology. Businesses like that tend to have volatile and t... Full story

Yahoo Finance • 7 months ago

ARK Invest's Cathie Wood Snags These 3 Bargains — Are They Right for Your Portfolio?

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Cathie Wood, co-founder, CEO, and investment manager of the ARK Invest family of exchange-traded funds, regularly discloses her stock tra... Full story

Yahoo Finance • 8 months ago

Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics, Inc. Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy Aligned with FDA on design for a new Phase 3 trial of NTLA-2001 f... Full story

Yahoo Finance • 10 months ago

A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now

You've no doubt seen mutual fund warnings that past performance isn't necessarily indicative of future results. This caution applies to stocks as well. However, it doesn't just mean that investments that have performed well in the past may... Full story

Yahoo Finance • 10 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders are probably feeling a little disappointed, since its shares fell 5.9% to US$26.10 in the week after its latest full-year results. Statutory results overall were mixed, with revenues c... Full story

Yahoo Finance • 10 months ago

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought

Cathie Wood's success is based on two main things: finding innovators and betting on them for the long term. The founder and chief executive officer of Ark Invest goes for innovators in all areas, from information technology to healthcare,... Full story

Yahoo Finance • 11 months ago

Top 11 CRISPR Stocks To Invest In

In this article, we discuss the top 11 CRISPR stocks to invest in. If you want to skip our discussion of the gene editing industry, head directly to Top 5 CRISPR Stocks To Invest In. Genome editing refers to a set of technologies enabling... Full story

Yahoo Finance • 11 months ago

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd... Full story

Yahoo Finance • 12 months ago

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024

Cathie Wood crushed it in 2023. Her flagship Ark Innovation ETF(NYSEMKT: ARKK) soared nearly 67%. The Ark Next Generation Internet ETF(NYSEMKT: ARKW) performed even better with an impressive 97% gain. If analysts are right, Wood could hav... Full story

Yahoo Finance • 12 months ago

2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex Pharmaceuticals. But CRISPR isn't the only biot... Full story

Yahoo Finance • last year

13 Most Promising Future Stocks To Buy According To Hedge Funds

In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. I... Full story

Yahoo Finance • last year

Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

CAMBRIDGE, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative single-dose therapeutics leveraging CRISPR-based te... Full story

Yahoo Finance • last year

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

FDA cleared NTLA-2001 IND application for first in vivo CRISPR candidate to enter late-stage clinical development; on track to initiate the MAGNITUDE pivotal Phase 3 trial in patients with transthyretin (ATTR) amyloidosis with cardiomyopat... Full story

Yahoo Finance • last year

Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting

Updated data from over 60 patients showed consistent, deep and durable serum TTR reduction achieved with a single dose of NTLA-2001, including in 29 patients who have now reached 12 months or more of follow-upNTLA-2001 was generally well-t... Full story